Contineum Therapeutics (CTNM) Liabilities and Shareholders Equity (2023 - 2026)

Contineum Therapeutics' Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $250.4 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 36.9% year-over-year to $250.4 million; the TTM figure through Jun 2026 stood at $979.2 million (up 20.88% YoY), while the FY2025 annual figure was $276.6 million, up 29.97% from the prior year.
• Liabilities and Shareholders Equity for Q2 2026 stood at $250.4 million, down from $261.3 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $276.6 million in Q4 2025, with the low at $123.6 million in Q1 2024.
• The 4-year median for Liabilities and Shareholders Equity is $212.8 million (2024), against an average of $205.9 million.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity surged 63.24% in 2024, then slipped 17.38% in 2025.
• Contineum Therapeutics' Liabilities and Shareholders Equity stood at $130.4 million in 2023, then surged by 63.24% to $212.8 million in 2024, then grew by 29.97% to $276.6 million in 2025, then dropped by 9.5% to $250.4 million in 2026.
• Business Quant data shows CTNM's Liabilities and Shareholders Equity at $250.4 million in Q2 2026, $261.3 million in Q1 2026, and $276.6 million in Q4 2025.